Navigation Links
Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals
Date:4/7/2008

" said Edward Lanphier, Sangamo's president and chief executive officer. "There is growing appreciation of the value of our technology as a rapid, reliable and highly specific tool to modify genes in eukaryotic cells and even whole organisms. As this increases we believe that there will be numerous applications of the technology in the generation of a variety of transgenic species as models of human disease and for drug development. "

ZFPs are the dominant class of naturally occurring transcription factors in organisms from yeast to humans. Transcription factors, which are found in the nucleus of every cell, bind to DNA to regulate gene expression. Though there are many kinds of transcription factors, only ZFPs are amenable to engineering and precise targeting to a particular gene or genes of interest. ZFNs are engineered forms of ZFPs that also contain a nuclease component, which can induce modification of a target gene of interest.

About Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on HIV/AIDS, neuropathic pain, cancer, nerve regeneration and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA- binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for therapeutic gene modification as a treatment
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
2. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
3. Sangamo BioSciences to Present at the 2007 BIO InvestorForum
4. Sangamo BioSciences Announces Third Quarter 2007 Conference Call and Webcast
5. Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting
6. Sangamo BioSciences to Present at the Piper Jaffray Health Care Conference
7. Sangamo BioSciences to Present at the BMO Capital Markets Health Care Conference
8. Sangamo BioSciences to Webcast Presentations at Investor and Analyst Briefing
9. Sangamo BioSciences Announces Fourth Quarter and Year-End 2007 Conference Call and Webcast
10. Sangamo BioSciences to Present at the BIO CEO & Investor Conference
11. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestone in Plant Agriculture Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Involution Studios , a ... a new infographic, Understanding Ebola . The ... designed, easy to follow informative tool for anyone wanting ... symptoms and prevention. , "As the news has spread ... Ebola outbreak represents not only a healthcare crisis with ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Grace Century, ... and healthcare projects, announces the addition of Dr. ... to its advisory team. Dr. Siddiqui will provide further ... , A graduate of University College Medical School ... degreed in medicine in 2001. With further certification as ...
(Date:10/22/2014)... --  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... and diseases, announced today that the U.S. Patent and ... a composition of matter patent application that covers the ... This is Synthetic Biologics, first allowed patent application directly ... the Company,s extensive C. difficile patent estate. ...
(Date:10/22/2014)... -- Research and Markets  has announced the addition ... Application, Geography - Global Analysis and Forecast (2014 - ... Organic electronics, also called as polymer electronics or plastic ... with small conductive molecules and electrically conductive polymers. It ... are carbon based, made using synthetic strategies developed in ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3
... May 24, 2010 Simbionix USA Corporation,the world,s leading provider of ... is launching,two new hands-on training systems- the Lap Nepherctomy simulation module and,the ... AUA annual meeting in San Francisco next week. , ... The Lap ...
... BEIJING , May 24 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: ... Weidong Yin ,Chairman, President & CEO, will present at the 2010 UBS Global ... London,England . Sinovac,s presentation is scheduled for Wednesday, June 2, 2010 ... , , ...
... ... ... plans to add to its natural color capabilities by investing $16 million at its Color ... facility dedicated wholly to natural colors production. The plant will be the largest and most ...
Cached Biology Technology:Simbionix to Reveal Two new Products at the Upcoming American Urology Association (AUA) Annual Meeting 2Simbionix to Reveal Two new Products at the Upcoming American Urology Association (AUA) Annual Meeting 3Sinovac to Present at 2010 UBS Global Specialty Pharmaceuticals Conference 2Sensient Technologies Corporation Announces Major Investment in Natural Colors 2
(Date:10/25/2014)... 2014 Research and Markets  has announced ... 2014-2018" report to their offering. ... on the basis of their physical or behavioral patterns. ... traits such as fingerprints, face recognition, DNA, palm print, ... as keystroke patterns and speech pattern/voice recognition. ...
(Date:10/22/2014)... The Nano-Bio Manufacturing Consortium (NBMC), an industry-academia ... (AFRL), has chosen a project proposed by the Arizona ... Arizona College of Medicine – Tucson ... is to assess different sweat collection methods and devices ... under a variety of human-body conditions, the results of ...
(Date:10/22/2014)... 21, 2014 Aware, Inc. (NASDAQ: AWRE ... reported financial results for its third quarter ended September 30, ... was $6.0 million, an increase of 40% compared to $4.3 ... the third quarter of 2014 was $4.1 million compared to ... income in the current three month period was primarily due ...
Breaking Biology News(10 mins):Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 2Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 3Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7
... hold great promise for benefiting degenerative diseases, and do ... grown in a manner compatible with clinical use (i.e., ... for immunosuppression. These were a few of a number ... by Evan Y. Snyder, M.D., Ph.D., and spearheaded by ...
... from another may depend on the number of receptors ... of receptors is controlled by levels of a ubiquitous ... found. , Everything from the ability to concentrate, perceive ... sclerosis, muscular dystrophy, post-traumatic stress syndrome and schizophrenia is ...
... launch of the first large-scale study to evaluate a ... today by study collaborators in the United States and ... participants at five sites throughout South Africa and is ... are part of the HIV Vaccine Trials Network (HVTN), ...
Cached Biology News:Stem cells act through multiple mechanisms to benefit mice with neurodegenerative disease 2Stem cells act through multiple mechanisms to benefit mice with neurodegenerative disease 3Stem cells act through multiple mechanisms to benefit mice with neurodegenerative disease 4Stem cells act through multiple mechanisms to benefit mice with neurodegenerative disease 5Bisexual fruit flies show new role for neurochemical 2Africa's first large-scale HIV vaccine study launches 2Africa's first large-scale HIV vaccine study launches 3Africa's first large-scale HIV vaccine study launches 4
HybriWell™ hybridization sealing system, 20 mm diameter chamber, 0.15 mm deep *set of 100*...
Recombinant Feline IL-5...
... Checker Kits provide two highly efficient methods ... time-consuming plasmid preparation. By using the large-scale ... need to do is to transfer partial ... the transformation plates into the solutions provided ...
Recombinant Equine IL-4, CF...
Biology Products: